January 23, 2021
Andrew Wei, MBBS, PhD, discusses the results from the phase 3 QUAZAR AML-001 Maintenance Trial of CC-486 for patients with acute myeloid leukemia in the first remission after intensive chemotherapy.
January 22, 2021
Jesus G. Berdeja, MD, discusses the findings from the phase 2 results of ciltacabtagene autoleucel as treatment of patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study.
January 21, 2021
Anne Chiang, MD, associate professor, Medical Oncology, Yale School of Medicine, discusses hard-to-treat lung cancer and how due to recent lung cancer innovations and treatment options, the tumor is becoming increasingly heterogeneous.
January 21, 2021
Amitkumar Mehta, MD, discusses the toxicity profile of parsaclisib in the phase 2 CITADEL-205 clinical trial of relapsed/refractory mantle cell lymphoma.
January 21, 2021
Steven Sherman, MD, FACE, provides insight on the treatment of radioactive iodine-refractory differentiated thyroid cancer and the management of adverse events.
January 20, 2021
Kerry Rogers, MD, discusses the findings observed in the phase 1b study of ianalumab in combination with ibrutinib as treatment of patients with chronic lymphocytic leukemia on ibrutinib therapy.
January 20, 2021
John H. Strickler, MD, discusses dosing of regorafenib in patients with colorectal cancer.
January 19, 2021
In an interview with Targeted Oncology, Naveen Pemmaraju, MD, discussed the potential role of an add-back strategy as treatment of patients with myelofibrosis who no longer benefited from prior ruxolitinib.
January 19, 2021
Kanwal Raghav, MBBS, MD, discusses factors that should be considered when deciding on treatment for a patient with metastatic colorectal cancer.
January 19, 2021
Mark J. Roschewski, MD, discusses the preliminary results of a phase 2 trial of copanlisib and rituximab as treatment of patients with untreated follicular lymphoma.